Fast Takes
Get ahead with this short-form webinar series focused on the next phase of pharma’s digital transformation.
Get our latest webinar insights in just three minutes:
Fast Take #1:
Patient Support, Reimagined
See how digital is accelerating patient support solutions while lessening the burden on care support teams.
Fast Take #2:
Patient Engagement, Personalized
Watch how digital solutions allow pharma to deliver personalized ‘white-glove’ patient journeys at scale.
Fast Take #3:
Enterprise Solutions, at Scale
How digital technology centralizes elements of patient support portfolio-wide without sacrificing brand identity.
Fast Take #4
Economic Impact, Proven
See the multi-million dollar ROI for pharma when digital improves adherence, persistence, efficiencies and more.
Fast Take #1: Patient Support Delivery Reimagined (3 minutes)
What to look for when implementing technology into existing model of support, in three minutes.
Fast Take #2: Patient Engagement, Personalized (3 minutes)
Take three minutes to see how digital solutions allow pharma to deliver personalized ‘white-glove’ patient journeys at scale.
Fast Take #3: Enterprise Solutions at Scale (3 minutes)
How digital technology centralizes elements of patient support portfolio-wide without sacrificing brand identity.
See the multi-million dollar ROI for pharma when digital improves adherence, persistence, efficiencies and more.
Digital Drug Companion
Medication Engagement Platform
Patients receive complete treatment management through a combination of advanced technology and expert knowledge. Connect patients with an innovative digital platform that drives medication engagement, integrates human support and delivers a holistic care experience.
Download Medisafe:
Latest From Medisafe
Transforming Breast Cancer Care: Proven Adherence Gains for Pharma Execs
Summary Breast cancer remains one of the most prevalent malignancies worldwide, with an estimated 287,850 new invasive cases and 43,250 breast cancer–related deaths projected in the United States in 2025 (American Cancer Society, 2025). Despite advances in targeted oral therapies for extended adjuvant treatment, real‐world studies find that up to 50% of patients discontinue or skip doses, undermining efficacy (Mayo Clinic, 2024). Pharmaceutical stakeholders…